Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Intra-Cellular Ther (ITCI)

Intra-Cellular Ther (ITCI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Implied Volatility Surging for Intra-Cellular (ITCI) Stock Options

Investors need to pay close attention to Intra-Cellular (ITCI) stock based on the movements in the options market lately.

ITCI : 25.52 (+0.35%)
Intra-Cellular Therapies Prices Public Offering of Common Stock

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 10,000,000 shares of its common stock...

ITCI : 25.52 (+0.35%)
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock

Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company, today announced that it has commenced an underwritten public offering of 10,000,000 shares of its common stock. In connection...

JPM : 136.68 (-0.12%)
ITCI : 25.52 (+0.35%)
Intra-Cellular Therapies to Present at the 38th Annual J.P. Morgan Healthcare Conference

Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D.,...

JPM : 136.68 (-0.12%)
ITCI : 25.52 (+0.35%)
Moving Average Crossover Alert: Intra-Cellular Therapies

Intra-Cellular Therapies, Inc. (ITCI) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

ITCI : 25.52 (+0.35%)
ITCI Crosses Above Average Analyst Target

In recent trading, shares of Intra-Cellular Therapies Inc have crossed above the average analyst 12-month target price of $23.00, changing hands for $36.51/share. When a stock reaches the target an analyst...

ITCI : 25.52 (+0.35%)
Company News For Dec 24, 2019

Companies in the news are: ACB, APA, ITCI, SRPT

SRPT : 118.33 (-3.79%)
ITCI : 25.52 (+0.35%)
APA : 30.87 (-2.74%)
ACB : 2.04 (+1.49%)
Look for Shares of Intra-Cellular T to Potentially Pullback after Yesterday's 173.15% Rise

Intra-Cellular T (NASDAQ:ITCI) traded in a range yesterday that spanned from a low of $23.75 to a high of $34.43. Yesterday, the shares gained 173.2%, which took the trading range above the 3-day high...

ITCI : 25.52 (+0.35%)
FDA Approves Intra-Cellular Therapies' Novel Antipsychotic, CAPLYTA(R) (lumateperone) for the Treatment of Schizophrenia in Adults

Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that CAPLYTA (lumateperone)...

ITCI : 25.52 (+0.35%)
Is the Options Market Predicting a Spike in Intra-Cellular Therapies (ITCI) Stock?

Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.

ITCI : 25.52 (+0.35%)
45.0% Return Seen to Date on SmarTrend Intra-Cellular T Call (ITCI)

SmarTrend identified an Uptrend for Intra-Cellular T (NASDAQ:ITCI) on October 29th, 2019 at $8.92. In approximately 2 months, Intra-Cellular T has returned 44.96% as of today's recent price of $12.93....

ITCI : 25.52 (+0.35%)
Theravance B has the Best Relative Performance in the Pharmaceuticals Industry (TBPH , ITCI , AERI , ZGNX , MDCO )

We looked at the Pharmaceuticals industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look...

AERI : 22.30 (-1.15%)
ITCI : 25.52 (+0.35%)
TBPH : 25.77 (-2.53%)
Intra-Cellular Therapies Highlights Lumateperone Presentations at the 58th Annual Meeting of the American College of Neuropsychopharmacology

Bipolar depression: Study 404, A Phase 3 Clinical Trial of lumateperone for the treatment of Bipolar Depression, investigating the potential of lumateperone as a new option for the treatment of depressive...

ITCI : 25.52 (+0.35%)
Uptrend Call Working As Intra-Cellular T Stock Rises 33.0% (ITCI)

SmarTrend identified an Uptrend for Intra-Cellular T (NASDAQ:ITCI) on October 29th, 2019 at $8.92. In approximately 1 month, Intra-Cellular T has returned 32.96% as of today's recent price of $11.86.

ITCI : 25.52 (+0.35%)
Intra-Cellular Therapies (ITCI) in Focus: Stock Moves 6.1% Higher

Intra-Cellular Therapies (ITCI) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

ITCI : 25.52 (+0.35%)
ANIK : 45.71 (-0.39%)
Top 5 Companies in the Pharmaceuticals Industry with the Best Relative Performance (DERM , ITCI , BMY , ZTS , PRGO )

Below are the top five companies in the Pharmaceuticals industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have...

BMY : 67.43 (unch)
DERM : 18.83 (-1.67%)
ITCI : 25.52 (+0.35%)
Best Relative Performance in the Pharmaceuticals Industry Detected in Shares of Dermira (DERM , NKTR , ITCI , RVNC , PRGO )

Here are the top 5 stocks in the Pharmaceuticals industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

DERM : 18.83 (-1.67%)
ITCI : 25.52 (+0.35%)
NKTR : 22.13 (-1.29%)
Watch for Intra-Cellular T to Potentially Pullback After Gaining 6.47% Yesterday

Intra-Cellular T (NASDAQ:ITCI) traded in a range yesterday that spanned from a low of $10.45 to a high of $11.07. Yesterday, the shares gained 6.5%, which took the trading range above the 3-day high...

ITCI : 25.52 (+0.35%)
Intra-Cellular T has the Best Relative Performance in the Pharmaceuticals Industry (ITCI , LCI , NKTR , ZGNX , AERI )

Here are the top 5 stocks in the Pharmaceuticals industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

ITCI : 25.52 (+0.35%)
LCI : 9.61 (+1.16%)
NKTR : 22.13 (-1.29%)
Intra-Cellular T Has Returned 10.3% Since SmarTrend Recommendation (ITCI)

SmarTrend identified an Uptrend for Intra-Cellular T (NASDAQ:ITCI) on October 29th, 2019 at $8.92. In approximately 1 month, Intra-Cellular T has returned 10.26% as of today's recent price of $9.84.

ITCI : 25.52 (+0.35%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS +0.44 , SEDG +0.93 , THC +0.25 , TER +2.04 , LITE +0.76
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar